Our current study indicated that upregulation of CD44 is correlated with aggressive behaviors during osteosarcoma progression, including metastasis, recurrence, poor response to chemotherapy, as well as unfavorable prognosis. The gene discussed is CD44; the disease is osteosarcoma.